You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

21 search results for: disease progression

Impact of Delayed EoE Diagnosis on <b>Disease</b> <b>Progression</b> and QoL

expert video

Impact of Delayed EoE Diagnosis on Disease Progression and QoL

2 min

Gastroenterology

Join Prof. Arjan Bredenoord as he discusses the importance of early diagnosis of EoE.

Gap in Care Leads to <b>Progression</b> of Fibrosis in EoE

expert video

Gap in Care Leads to Progression of Fibrosis in EoE

1 min

Gastroenterology

Dr. Evan Dellon discusses the clinical implications of gaps in medical care on the risk of fibrotic progression in EoE.

expert video

UEGW 2024 | WHY Is Long-Term Management of EoE Important?

10 min

Gastroenterology

Prof. Salvatore Oliva discusses the impact of chronic type 2 inflammation on EoE progression, highlighting the need for long-term management.

interactivity

GINA Guidelines For Improved Outcomes With Effective Management of Pediatric Asthma

5 min

Pulmonology

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on <b>Disease</b> Remodeling

expert video

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

15 min

Pulmonology

Professor Paola Rogliani examines the role of IL-33 in the pathophysiology of COPD, focusing on its contribution to airway inflammation, remodeling, and disease progression.

expert video

Managing the Risk of Fibrostenosis in EoE

2 min

Gastroenterology

Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.

Worsening <b>Disease</b> Results in a Vicious Cycle of COPD

interactivity

Worsening Disease Results in a Vicious Cycle of COPD

5 min

Pulmonology

Learn about the disease burden and heterogeneity of COPD

Importance of Assessing Multiple <b>Disease</b> Domains in EoE

expert video

Importance of Assessing Multiple Disease Domains in EoE

2 min

Gastroenterology

Prof. Arjan Bredenoord and Dr. Evan Dellon emphasize the need to assess multiple disease domains to get the complete picture of patients’ EoE.

expert video

Type 2 Inflammation

2 min

Dermatology

In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Peter Leo, MD and Dr. Amy Paller, MD discusses the multifaceted nature of atopic diseases, including environmental triggers, key Type 2 inflammatory mechanisms, and associated health risks, to understand the importance of early intervention in managing and potentially modifying disease progression.

videoanimation

EoE Burden and Pathophysiology of Type 2 Inflammation

3 min

Gastroenterology

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

expert video

What Are the Key Inflammatory Processes in Patients with COPD?

2 min

Pulmonology

Dr. Klaus Rabe, MD, PhD, discusses the key inflammatory processes in patients with COPD and their implications for patient care.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region